Waldenstrom macroglobulinemia market expected to grow through 2036 as targeted therapies expand
AI Summary- DelveInsight published a report forecasting the Waldenstrom macroglobulinemia treatment market through 2036.
- The United States recorded approximately 3 annual cases per million and 1,000 to 1,500 new diagnoses.
- Cellectar Biosciences reported an 83.6% overall response rate for Iopofosine I-131.